1. Finland Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Herantis Pharma Oyj

Herantis Pharma Oyj

HRTIS.HE
Herantis Pharma OyjFI flagNASDAQ Helsinki
1.82
EUR
+0.03
- -
48.34MMarket Cap
Herantis Pharma Oyj
HRTIS.HE
(NASDAQ Helsinki)

Recent

price

1.82

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
- -
- -
- -
- -
- -
0.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-1.19
-71.16
-0.64
-3.05
-3.75
-1.02
-0.42
-0.81
-1.3
-1.18
-2.31
-0.64
0.02
- -
- -
Basic EPS, GAAP
- -
-417.42
-0.88
-1.59
-1.73
-0.7
-0.5
-0.72
-0.97
-1.1
-0.89
-0.61
-0.27
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-1.85
-478.01
-2.81
-3.99
-6.3
-7.25
-6.49
-7.3
-7.44
-7.06
-6.46
-5.14
-4.36
- -
- -
Book Value per Share
-1.29
-372.2
-2.04
1.41
-0.57
-1.32
-0.38
-0.96
-0.32
0.61
0.04
- -
0.27
- -
- -
Tangible Book Value per Share
1
- -
1
3
4
4
5
5
6
8
10
15
17
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
-957,080.22
-826,918.33
-17,476.65
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
2
9
1
1
1
1
1
- -
- -
- -
- -
- -
Depreciation Expense
-1
- -
-1
-8
-16
-4
-2
-4
-8
-9
-24
-9
- -
-5
-7
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
-1,044,555.44
-820,699.92
-17,493.77
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
-1
10
5
2
4
1
5
11
5
4
5
2
2
Working Capital
1
2
2
6
8
8
6
6
7
6
4
4
- -
- -
- -
LT Debt
-1
- -
- -
22
6
2
4
- -
2
8
1
- -
5
- -
-2
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
3.34
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-1.14
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-953.41%
-1,530.94%
594.48%
Free Cash Flow
6.41%
-1.86%
-6.87%
Net Income, GAAP
-176.14%
-367.38%
34.03%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.02
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Sernova Corp. (SEOVF)
Silence Therapeutics plc (SLN)
Haisco Pharmaceutical Group Co., Ltd. (002653.SZ)
Soligenix Inc. Warrant (SNGXW)
Voyager Therapeutics, Inc. (VYGR)
Ergomed plc (2EM.DE)
Business
Herantis Pharma Oyj Herantis Pharma Oyj is a clinical-stage biotechnology company that develops disease-modifying therapies for Parkinson's disease and other neurodegenerative disorders; its lead product candidate, HER-096, is an advanced small synthetic chemical peptidomimetic molecule based on the active site of the cerebral dopamine neurotrophic factor (CDNF) protein, designed for subcutaneous administration to provide neuroprotection by stopping or reversing disease progression. The company focuses on innovative treatments addressing unmet clinical needs in neurology, with HER-096 currently advancing through clinical development following positive topline results from a Phase 1b trial in Parkinson's patients that met all primary and secondary endpoints for safety, tolerability, and pharmacokinetics. Founded in 2008 and headquartered in Espoo, Finland, Herantis Pharma Oyj operates primarily in Europe with global ambitions for its pipeline and employs approximately 11-13 staff. Recent developments include the successful completion of a six-month GLP toxicology study for HER-096 in November 2025, plans to initiate a Phase 2 efficacy trial in early-stage Parkinson's patients during 2026, and ongoing funding secured through EUR 3.6 million in research grants from The Michael J. Fox Foundation and Parkinson's Virtual Biotech for the Phase 1b trial and biomarkers, supplemented by EUR 2.5 million from the European Innovation Council Accelerator's ReTreatPD project and eligibility for up to EUR 15 million equity from the EIC Fund; the company also raised EUR 5.2 million via a directed share issue in February 2025 to support operations through Q2 2026 while pursuing pharmaceutical partnerships.